Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 7OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Breast 1

Conditions

Prostatic Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Breast Neoplasms 1

Interventions

Cyclophosphamide 548pembrolizumab 385Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Has results × darolutamide × Clear all
NCT04737109 2023-11-13

ADDItion

Big Ten Cancer Research Consortium

Phase 1/2 Terminated
6 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT04237584 2022-10-07

ESCALATE

MANA RBM

Phase 3 Terminated
23 enrolled 11 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT03004534 2020-04-03

A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide

Translational Research in Oncology

Phase EARLY_PHASE1 Completed
36 enrolled 10 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡